Multivariate analyses for the impact of Ki-67 on various pathologic outcomes after surgery.

Multivariate analyses for the impact of Ki-67 on various pathologic outcomes after surgery.</p

Multivariate analyses using Cox proportional hazard model on biochemical recurrence after propensity score matching (Ki-67 as categorical variable).

Multivariate analyses using Cox proportional hazard model on biochemical recurrence after propensity score matching (Ki-67 as categorical variable).</p

Clinical and pathologic characteristics by Ki-67 expression.

Clinical and pathologic characteristics by Ki-67 expression.</p

Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: A propensity score matched study - Fig 1

Kaplan-Meier analysis for biochemical recurrence free survival according to the expression of Ki-67 among the entire 1,561 patients (A) and among the 732 patients after propensity scored matching (B).</p

Differences of post-operative complications according to type of surgery in the patients with upper tract urothelial cancer.

Differences of post-operative complications according to type of surgery in the patients with upper tract urothelial cancer.</p

Multivariate Cox proportional hazards analyses for surgical approaches estimating each survival outcome.

Multivariate Cox proportional hazards analyses for surgical approaches estimating each survival outcome.</p

Kaplan-Meier analysis of survival outcomes of patients treated with nephroureterectomy for non-metastatic upper tract urothelial cell carcinoma.

Kaplan-Meier analysis of survival outcomes of patients treated with nephroureterectomy for non-metastatic upper tract urothelial cell carcinoma.</p

Kaplan-Meier curves for biochemical recurrence-free survival according to: (A) the history of DM; (B) HbA1c level.

<p>DM = diabetes mellitus, HbA1c = hemoglobin A1c</p

Patients’ characteristics.

<p>BMI = body mass index; PSA = prostatic specific antigen; DM = diabetes mellitus; HbA1c = hemoglobin A1c</p><p>Patients’ characteristics.</p

Differences in clinico-pathologic findings according to DM history and HbA1c level.

<p>DM = diabetes mellitus; HbA1c = hemoglobin A1c; PSA = prostate specific antigen; BMI = body mass index; PV = prostate volume; PSM = positive surgical margin; SVI = seminal vesicle invasion; EPE = extraprostatic extension; LNI = lymph node invasion; BCR = biochemical recurrence.</p><p>Differences in clinico-pathologic findings according to DM history and HbA1c level.</p